Datasheet Brochure Journal


Electroporation with chemotherapy has been in clinical use for more than 15 years and in 2006 the Eu­ropean Standard Operating Procedure (ESOPE) which described the standard delivery of the proce­dure including chemotherapy dose.

Of great benefit, due to the greater conductivity of tumour tissue, the surrounding healthy tissue structures are not damaged in the process.

The effectiveness of electroporation in tumour ablation clinically has been reported by a growing number of clini­cians in the US and Europe with excellent quality of life and tumour reduction reported for both cutaneous and in­traluminal applications.

The EndoVE system has been assessed in clinical trials for patients with inoperable colorectal and oesophageal cancer. The clinical evidence to date with electroporation has demonstrated its excellent efficacy in tumour treatment even in cases where tumours were previously unres­ponsive to chemotherapy or radiotherapy.

  • Demonstrated to be safe and effective
  • Precision delivery of non-thermal ablation which targets tumour tissue whilst preserving surrounding healthy tissue structures
  • ePORE and EndoVE are repeatable and leave standard treatment options available
  • Delivered under light sedation, day case, cost effective
  • Simple standard connection for endoscopes between 9mm and 10mm
  • Connects to a vacuum which draws the tumour tissue into the chamber this can be viewed via the window at the head of the electrode
  • Ease of use

Product Video

Product Variations

Product Code Description
EndoVE 700209 EndoVE Electroporation Probe
ePORe MMH1 ePORe MMH1 Generator
Extension Lead MS-19-05 Low Frequency Extension Lead for EndoVE
Extension Lead MS-18-07 High Frequency Extension Lead for EndoVE

Long term survival outcome from Colorectal Cancer cases based on Immune reactivity of tumour

Survival prospects from 155 node negative surgically operated Dukes B colorectal cancer patients (A) from the Cork Cancer Research Centre, Mercy University Hospital, Cork and 260 Dukes B rectal carcinomas (B) from St. Marks Hospital, London. Groups were divided in four according to the inflammatory response to their primary tumours. (I) Jass and Crohn’s-like reactions, both present, (II) Jass positive, Crohn’s-like negative, (III) Jass negative, Crohns-like positive, (IV) Jass and Crohn’s like reactions, both negative.

Colorectal patients treated with electroporation have recorded an inflammatory reaction post treatment which may faciliate an immune engagement similar to the patients see in group (I).

Cutaneous Efficacy: Electroporation & Low Dose Chemo

171 treated tumour nodules: Complete response (CR) observed in 73% of cases and a partial response in 11%. Includes tumours previously unresponsive to chemo and or radiotherapy.

Marty, Michel; Sersa, Gregor; et al. (2006). "Electrochemotherapy – An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study". European Journal of Cancer Supplements. 4 (11): 3–13

Clinical Results

ePORE Therapy

Key Patient Benefit:

Healthy tissue is preserved

Clover et al., Electrochemotherapy for the treatment of primary basal cell carcinoma; A randomised control trial comparing electrochemotherapy and surgery with five year follow up. Eur J of Sur Onc 2019

87.5% Curative outcome after 5yrs

Pre Clinical Results:

Forde et al., Preclinical evaluation of an endoscopic electroporation system Endoscopy 2016

Canine Colorectal Lymphoma

“Preclinical evaluation of an endoscopic electroporation system” Endoscopy, May 2016

By continuing to browse or by clicking “Accept All Cookies,” you agree to the storing of first and third-party cookies on your device to enhance site navigation and analyse site usage. Find out more about our cookie policy.

By continuing to browse or by clicking “Accept All Cookies,” you agree to the storing of first and third-party cookies on your device. View our Cookie Policy.

> Cookie Settings

Cookie Preference Settings


Your Privacy

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, your device or used to make the site work as you expect it to. The information does not usually identify you directly, but it can give you a more personalized web experience. You can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, you should know that blocking some types of cookies may impact your experience on the site and the services we are able to offer.

Always Active

Essential Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site may not work then.

Cookies Used